Results for 'emerging agents'
Browse oncology articles matching emerging agents — expert analysis, clinical perspectives, and industry updates from across drug development and care delivery. Use the tabs above for podcasts, press releases, partners, and people for the same search.
Carina Dolan, PharmD, BCOP
Opportunities and challenges in biosimilar uptake in oncology
Trastuzumab, Rituximab, biosimiliar agents, emerging agents, cetuximab, bevacizumab, clinical trials, biosimiliars
The U.S. has 10 approved biosimilars, including 3 for oncology, with many more in development, potentially increasing access to expensive biologics. Acceptance by healthcare providers and patients requires extensive education, resolving concerns about immunogenicity, and ensuring interchangeability.…
Jun 26th • 7 mins read
Reagent Solutions to Support Outbreak Response Against Bundibugyo Virus
Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegaviral…
Sep 17th • 0 min read
Thomas Schmitt
Reagent Solutions to Support Outbreak Response Against Bundibugyo Virus
Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegaviral…
Sep 4th • 0 min read
Thomas Schmitt
Reagent Solutions to Support Outbreak Response Against Bundibugyo Virus
Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegaviral…
Sep 4th • 0 min read
Mythili Shastry, PhD, Avantika Gupta, PhD, Sarat Chandarlapaty, MD, PhD, Matthew Young, MD, Thomas Powles, MD, and Erika Hamilton, MD
Rise of Antibody-Drug Conjugates: The Present and Future
Antibody-drug conjugates (ADCs) are designed for targeted cancer therapy by delivering cytotoxic agents specifically to tumor cells, minimizing harm to normal cells. ADCs have evolved significantly since the first FDA approval in 2000, with advancements leading to approvals for various tumor type…
May 25th • 20 mins read